Pulse Biosciences (NASDAQ:PLSE) Sets New 52-Week High – Time to Buy?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $51.00 and last traded at $50.1640, with a volume of 14790 shares. The stock had previously closed at $50.33.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Canaccord Genuity Group lifted their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Mizuho set a $45.00 target price on Pulse Biosciences in a research report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Price Performance

The stock has a market capitalization of $3.65 billion, a P/E ratio of -44.64 and a beta of 1.63. The stock’s fifty day moving average is $36.93 and its 200-day moving average is $27.60.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. On average, research analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Buying and Selling at Pulse Biosciences

In related news, COO Liane Rae Teplitsky bought 1,036 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer owned 1,036 shares in the company, valued at $49,966.28. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders purchased 4,095 shares of company stock valued at $199,931. 74.00% of the stock is currently owned by company insiders.

Institutional Trading of Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences during the 2nd quarter worth $28,000. Tower Research Capital LLC TRC lifted its position in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences in the second quarter valued at about $158,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.